Literature DB >> 31485719

Cardiopulmonary interaction in heart or lung disease: physiology, disturbances, and their clinical implications.

S Rosenkranz1, J Bauersachs2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31485719     DOI： 10.1007/s00059-019-4832-5

Source DB:  PubMed          Journal:  Herz        ISSN： 0340-9937            Impact factor:   1.443


× No keyword cloud information.
  10 in total

1.  Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Garvan C Kane; Vojtech Melenovsky; Thomas P Olson
Journal:  Eur Heart J       Date:  2016-06-26       Impact factor: 29.983

Review 2.  What can we learn from pulmonary function testing in heart failure?

Authors:  Helgo Magnussen; Marco Canepa; Peter Emilio Zambito; Vito Brusasco; Thomas Meinertz; Stephan Rosenkranz
Journal:  Eur J Heart Fail       Date:  2017-08-14       Impact factor: 15.534

3.  Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.

Authors:  Marco Canepa; Ewa Straburzynska-Migaj; Jaroslaw Drozdz; Carla Fernandez-Vivancos; Jose Manuel Garcia Pinilla; Noemi Nyolczas; Pier Luigi Temporelli; Alexandre Mebazaa; Mitja Lainscak; Cécile Laroche; Aldo Pietro Maggioni; Massimo F Piepoli; Andrew J S Coats; Roberto Ferrari; Luigi Tavazzi
Journal:  Eur J Heart Fail       Date:  2017-09-26       Impact factor: 15.534

Review 4.  Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services.

Authors:  Nathaniel M Hawkins; Sean Virani; Claudio Ceconi
Journal:  Eur Heart J       Date:  2013-07-05       Impact factor: 29.983

5.  Effect of Indacaterol/Glycopyrronium on Pulmonary Perfusion and Ventilation in Hyperinflated Patients with Chronic Obstructive Pulmonary Disease (CLAIM). A Double-Blind, Randomized, Crossover Trial.

Authors:  Jens Vogel-Claussen; Christian-Olaf Schönfeld; Till F Kaireit; Andreas Voskrebenzev; Christoph P Czerner; Julius Renne; Hanns-Christian Tillmann; Korbinian Berschneider; Simone Hiltl; Johann Bauersachs; Tobias Welte; Jens M Hohlfeld
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

6.  β-Blockers are associated with a reduction in COPD exacerbations.

Authors:  Surya P Bhatt; James M Wells; Gregory L Kinney; George R Washko; Matthew Budoff; Young-Il Kim; William C Bailey; Hrudaya Nath; John E Hokanson; Edwin K Silverman; James Crapo; Mark T Dransfield
Journal:  Thorax       Date:  2015-08-17       Impact factor: 9.139

7.  Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial.

Authors:  Marco Canepa; Pier Luigi Temporelli; Andrea Rossi; Andrea Rossi; Lucio Gonzini; Gian Luigi Nicolosi; Lidia Staszewsky; Roberto Marchioli; Aldo Pietro Maggioni; Luigi Tavazzi
Journal:  Cardiology       Date:  2016-09-08       Impact factor: 1.869

8.  Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.

Authors:  Jens M Hohlfeld; Jens Vogel-Claussen; Heike Biller; Dominik Berliner; Korbinian Berschneider; Hanns-Christian Tillmann; Simone Hiltl; Johann Bauersachs; Tobias Welte
Journal:  Lancet Respir Med       Date:  2018-02-21       Impact factor: 30.700

9.  Pulmonary hypertension due to left heart disease.

Authors:  Jean-Luc Vachiéry; Ryan J Tedford; Stephan Rosenkranz; Massimiliano Palazzini; Irene Lang; Marco Guazzi; Gerry Coghlan; Irina Chazova; Teresa De Marco
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 10.  Left ventricular heart failure and pulmonary hypertension.

Authors:  Stephan Rosenkranz; J Simon R Gibbs; Rolf Wachter; Teresa De Marco; Anton Vonk-Noordegraaf; Jean-Luc Vachiéry
Journal:  Eur Heart J       Date:  2015-10-27       Impact factor: 29.983
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.